Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis buys Protez for $100mm, plus $300mm in earn-outs

Executive Summary

Novartis has agreed to acquire privately held Protez Pharmaceuticals (antibiotics) for $100mm, plus earn-outs of up to $300mm if its lead candidate reaches clinical goals, gains regulatory approvals, and achieves commercial targets.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash
    • Acquisition of Private Biotech

Related Companies